Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zur Untersuchung der Sicherheit und Wirksamkeit von Tapinarof-Creme, 1 %, bei Teilnehmern im Alter von 3 Monaten bis < 24 Monaten mit atopischer Dermatitis (Adoring)

6. November 2026 aktualisiert von: Organon and Co

Eine randomisierte, doppelblinde, fahrzeugkontrollierte (Periode 1) und offene (Periode 2) Phase-3-Studie zur Untersuchung der Sicherheit und Wirksamkeit von Tapinarof-Creme, 1 %, bei pädiatrischen Teilnehmern im Alter von 3 Monaten bis < 24 Monaten mit atopischer Dermatitis

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Studientyp

Interventionell

Einschreibung (Tatsächlich)

187

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Alberta
      • Calgary, Alberta, Kanada, T2J 7E1
        • Dermatology Research Institute
      • Red Deer, Alberta, Kanada, T4P 1K4
        • CARe Clinic (Central Alberta Research Clinic)
    • British Columbia
      • Surrey, British Columbia, Kanada, V3R 6A7
        • Dr. Chih-Ho Hong Medical Inc.
    • Manitoba
      • Winnipeg, Manitoba, Kanada, R3J 0S9
        • Manitoba Allergy Research Inc.
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3K 5R3
        • Maritime Dermatology
    • Ontario
      • Burlington, Ontario, Kanada, L7L 6W6
        • Halton Pediatric Allergy
      • Hamilton, Ontario, Kanada, L8S 1G5
        • Triple A Lab Inc.
      • Niagara Falls, Ontario, Kanada, L2H 1C4
        • Allergy Research Canada Inc.
    • Saskatchewan
      • Regina, Saskatchewan, Kanada, S4V 1R9
        • Dr. Rachel Asiniwasis Medical Professional Corporation
      • Saskatoon, Saskatchewan, Kanada, S7K 2C1
        • Skinsense Medical Research
    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35209
        • AllerVie Clinical Research
    • Arkansas
      • Bryant, Arkansas, Vereinigte Staaten, 72022
        • Dermatology Trial Associates
    • California
      • Los Angeles, California, Vereinigte Staaten, 90045
        • Dermatology Research Associates
      • Sacramento, California, Vereinigte Staaten, 95815
        • Integrative Skin Science and Research
      • San Diego, California, Vereinigte Staaten, 92123
        • Allergy and Asthma Medical Group and Research Center
      • Thousand Oaks, California, Vereinigte Staaten, 91320
        • Clinical Trials Research Institute
    • Colorado
      • Castle Rock, Colorado, Vereinigte Staaten, 80109
        • Clarity Dermatology
    • Florida
      • Boca Raton, Florida, Vereinigte Staaten, 33486
        • Skin Care Research, LLC.
      • Jacksonville, Florida, Vereinigte Staaten, 32256
        • APEX Clinical Trials
      • Wellington, Florida, Vereinigte Staaten, 33449
        • TruDerm Research
    • Georgia
      • Cumming, Georgia, Vereinigte Staaten, 30040
        • Cleaver Medical Group Dermatology, Inc
    • Idaho
      • Meridian, Idaho, Vereinigte Staaten, 83646
        • Ada West Research
    • Illinois
      • Skokie, Illinois, Vereinigte Staaten, 60077
        • Endeavor Health Clinical Trials Center
    • Indiana
      • Indianapolis, Indiana, Vereinigte Staaten, 46250
        • Dawes Fretzin Clinical Research Group, LLC
      • Plainfield, Indiana, Vereinigte Staaten, 46168
        • The Indiana Clinical Trials Center, PC
    • Kentucky
      • Bowling Green, Kentucky, Vereinigte Staaten, 42104
        • Equity Medical, LLC
    • Maryland
      • Rockville, Maryland, Vereinigte Staaten, 20850
        • Lawrence J Green, MD LLC
    • Michigan
      • Auburn Hills, Michigan, Vereinigte Staaten, 48326
        • Oakland Hills Dermatology
    • Minnesota
      • New Brighton, Minnesota, Vereinigte Staaten, 55112
        • Minnesota Clinical Study Center
    • Mississippi
      • Ridgeland, Mississippi, Vereinigte Staaten, 39157
        • SKY Integrative Medical Center
    • Missouri
      • Saint Joseph, Missouri, Vereinigte Staaten, 64506
        • MediSearch Clinical Trials
    • Nevada
      • Reno, Nevada, Vereinigte Staaten, 89509
        • Skin Cancer and Dermatology Institute
    • New York
      • Kew Gardens, New York, Vereinigte Staaten, 11415
        • Forest Hills Dermatology Group
      • New York, New York, Vereinigte Staaten, 10012
        • Bobby Buka MD, PC
      • The Bronx, New York, Vereinigte Staaten, 10455
        • Equity Medical, LLC
    • North Carolina
      • Chapel Hill, North Carolina, Vereinigte Staaten, 27516
        • The University of North Carolina Dermatology and Skin Cancer Center
    • Ohio
      • Fairborn, Ohio, Vereinigte Staaten, 45324
        • Dermatologists of Central States, LLC
    • Oklahoma
      • Oklahoma City, Oklahoma, Vereinigte Staaten, 73120
        • Allergy Asthma and Clinical Research Center
    • Oregon
      • Portland, Oregon, Vereinigte Staaten, 97210
        • Oregon Dermatology and Research Center
      • Portland, Oregon, Vereinigte Staaten, 97239
        • Oregon Health & Science University
    • South Carolina
      • Charleston, South Carolina, Vereinigte Staaten, 29425
        • Medical University of South Carolina
      • North Charleston, South Carolina, Vereinigte Staaten, 29420
        • National Allergy and Asthma Research, LLC.
    • Texas
      • Bellaire, Texas, Vereinigte Staaten, 77401
        • The University of Texas Health Science Center at Houston
      • Dallas, Texas, Vereinigte Staaten, 75230
        • Dermatology Treatment and Research Center
      • Southlake, Texas, Vereinigte Staaten, 76092
        • Stryde Research - Epiphany Dermatology
    • Washington
      • Spokane, Washington, Vereinigte Staaten, 99202
        • Dermatology Specialists of Spokane

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

3 Monate bis 1 Jahr (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
  • Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
  • Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
  • Legal guardian or primary caregiver is able and willing to adhere to protocol requirements

Exclusion Criteria:

  • Significant neurological disorder or history of seizure
  • Know clinically significant cardiac rhythm or cardiac disorder
  • History of sudden infant death in a sibling
  • Clinically significant chromosome abnormality
  • History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
  • Diseases that could cause pruritic and/or sleep disruption
  • Immunocompromised
  • Current chronic or acute infection requiring treatment
  • Use of prohibited medication(s) or procedure(s)
  • Use of prohibited medications by breastfeeding mother if breastfeeding participant

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Tapinarof cream

Tapinarof cream, 1%, applied topically once daily

Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.

Andere Namen:
  • DMVT-505
  • OG-0505
  • GSK2894512A
  • GSK28994512
  • STI-1001
  • WBI-1001
Placebo-Komparator: Vehicle cream

Vehicle cream is applied topically once daily for up to 8-weeks.

Applied topically once daily to lesions on participant's skin during the Double-Blind period.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
Zeitfenster: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
Zeitfenster: Baseline to the end of the Open-Label Period, up to 56 weeks.

The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

Baseline to the end of the Open-Label Period, up to 56 weeks.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
Zeitfenster: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
Zeitfenster: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% [10 handprints], upper extremities = 20% [20 handprints], trunk (including axillae and groin) = 30% [30 handprints], lower extremities, including buttocks, = 40% [40 handprints]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
Zeitfenster: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Zeitfenster: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Zeitfenster: Baseline to the end of the Open-Label Period, up to 56 weeks

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to the end of the Open-Label Period, up to 56 weeks
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Zeitfenster: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Zeitfenster: Baseline to the end of the Open-Label Period, up to 56 weeks.

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to the end of the Open-Label Period, up to 56 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Zeitfenster: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Zeitfenster: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Zeitfenster: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Zeitfenster: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Clinical Lead Late-Stage Clinical Development, Organon and Co

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

29. Dezember 2025

Primärer Abschluss (Geschätzt)

1. August 2027

Studienabschluss (Geschätzt)

1. August 2027

Studienanmeldedaten

Zuerst eingereicht

21. November 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. Dezember 2025

Zuerst gepostet (Tatsächlich)

4. Dezember 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

10. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. November 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren